World Journal of Surgery

, Volume 34, Issue 9, pp 2083–2089 | Cite as

Phase II Clinical Trial of Postoperative S-1 Monotherapy for Gastric Cancer Patients with Free Intraperitoneal Cancer Cells Detected by Real-Time RT-PCR

  • Seiji Ito
  • Yasuhiro Kodera
  • Yoshinari Mochizuki
  • Taiki Kojima
  • Hayao Nakanishi
  • Yoshitaka Yamamura



We have previously reported the molecular detection of peritoneal micrometastases in patients with gastric cancer by quantifying carcinoembryonic antigen (CEA) mRNA in the peritoneal washes. Patients with CEA mRNA exceeding a cutoff value have a significant risk for developing peritoneal carcinomatosis, but optimal treatment for this population remains unknown.


CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy. Overall survival, the primary endpoint of this phase II trial, was compared with the historical control, which is comprised of CEA mRNA (+) patients who were not given postoperative chemotherapy.


A total of 32 patients with CEA mRNA (+) gastric cancer were enrolled. Twelve patients (37.5%) relapsed; ten showed peritoneal relapse. Three-year survival was similar between the study population and the historical control (67.3% vs. 67.1%, respectively).


S-1 monotherapy, which significantly reduced risk for recurrence in stage II/III gastric carcinoma in another phase III trial, seems not to be as effective in eradicating free cancer cells in the abdominal cavity.


Gastric Cancer Historical Control Peritoneal Carcinomatosis Postoperative Adjuvant Chemotherapy Peritoneal Wash 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was supported in part by a grant from the Ministry of Health, Labor and Welfare, Japan and Ministry of Education, Science, Sports, Culture and Technology, Japan.

Conflict of interest

There are no conflicts of interest to report.


  1. 1.
    Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  2. 2.
    Boku T, Nakane Y, Minoura T et al (1990) Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg 77:436–439CrossRefPubMedGoogle Scholar
  3. 3.
    Kodera Y, Nakanishi H, Yamamura Y et al (1998) Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer 79:429–433CrossRefPubMedGoogle Scholar
  4. 4.
    Ito S, Nakanishi H, Kodera Y et al (2005) Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients. Br J Cancer 93:986–992CrossRefPubMedGoogle Scholar
  5. 5.
    Kodera Y, Nakanishi H, Ito S et al (2002) Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Ann Surg 235:499–506CrossRefPubMedGoogle Scholar
  6. 6.
    Nakanishi H, Kodera Y, Torii A et al (1997) Detection of carcinoembryonic antigen-expressing free tumor cells in peritoneal washes from patients with gastric carcinoma by polymerase chain reaction. Jpn J Cancer Res 88:687–692PubMedGoogle Scholar
  7. 7.
    Nakanishi H, Kodera Y, Yamamura Y et al (2000) Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcycler. Int J Cancer 89:411–417CrossRefPubMedGoogle Scholar
  8. 8.
    Chaudhuri TR, Mountz JM, Rogers BE et al (2001) Light-based imaging of green fluorescent protein-positive ovarian cancer xenografts during therapy. Gynecol Oncol 82:581–589CrossRefPubMedGoogle Scholar
  9. 9.
    Kurebayashi J, Nukatsuka M, Fujioka A et al (1997) Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. Clin Cancer Res 3:653–659PubMedGoogle Scholar
  10. 10.
    Yokoyama H, Nakanishi H, Kodera Y et al (2006) Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent protein-tagged human gastric cancer cell line. Clin Cancer Res 12:361–368CrossRefPubMedGoogle Scholar
  11. 11.
    Hermans J, Bonenkamp JJ, Boon MC et al (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441–1447PubMedGoogle Scholar
  12. 12.
    Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557CrossRefPubMedGoogle Scholar
  13. 13.
    Koizumi W, Kurihara M, Nakano S et al (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191–197CrossRefPubMedGoogle Scholar
  14. 14.
    Sakata Y, Ohtsu A, Horikoshi N et al (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720CrossRefPubMedGoogle Scholar
  15. 15.
    Kinoshita T, Nashimoto A, Yamamura Y et al (2004) Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 7:104–109CrossRefPubMedGoogle Scholar
  16. 16.
    Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820CrossRefPubMedGoogle Scholar
  17. 17.
    Nakanishi H, Kodera Y, Yamamura Y et al (1999) Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies. Cancer Chemother Pharmacol 43(Suppl):S32–S36CrossRefPubMedGoogle Scholar
  18. 18.
    Wolfrum F, Vogel I, Fandrich F et al (2005) Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 390:430–441CrossRefPubMedGoogle Scholar
  19. 19.
    Mori K, Suzuki T, Uozaki H et al (2007) Detection of minimal gastric cancer cells in peritoneal washings by focused microarray analysis with multiple markers: clinical implications. Ann Surg Oncol 14:1694–1702CrossRefPubMedGoogle Scholar
  20. 20.
    Fujita Y, Terashima M, Hoshino Y et al (2006) Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer. Gastric Cancer 9:308–314CrossRefPubMedGoogle Scholar
  21. 21.
    Mimori K, Fukagawa T, Kosaka Y et al (2008) Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res 14:2609–2616CrossRefPubMedGoogle Scholar
  22. 22.
    Kodera Y, Ito S, Mochizuki Y et al (2009) A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol 35:1158–1163PubMedGoogle Scholar
  23. 23.
    Dalal KM, Woo Y, Kelly K et al (2008) Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer 11:206–213CrossRefPubMedGoogle Scholar
  24. 24.
    Kodera Y, Nakanishi H, Ito S et al (2006) Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of follow-up. J Am Coll Surg 202:231–236CrossRefPubMedGoogle Scholar
  25. 25.
    Tsuburaya A, Sakamoto J, Morita S et al (2005) A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit). Trial Jpn J Clin Oncol 35:672–675CrossRefGoogle Scholar
  26. 26.
    Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277–283CrossRefPubMedGoogle Scholar
  27. 27.
    Kang Y, Chang H, Zang D et al (2008) Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: a randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short- term doxifluridine (Mf) (AMC 0101) (NCT00296322). J Clin Oncol 26(Suppl):abstr LBA4511Google Scholar
  28. 28.
    Kodera Y, Ito Y, Ito S et al (2007) Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology 54:960–963PubMedGoogle Scholar
  29. 29.
    Ohashi N, Kodera Y, Nakanishi H et al (2005) Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 27:637–644PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2010

Authors and Affiliations

  • Seiji Ito
    • 1
  • Yasuhiro Kodera
    • 4
  • Yoshinari Mochizuki
    • 1
  • Taiki Kojima
    • 1
  • Hayao Nakanishi
    • 2
    • 3
  • Yoshitaka Yamamura
    • 1
  1. 1.Department of Gastroenterological SurgeryAichi Cancer Center HospitalNagoyaJapan
  2. 2.Division of Oncological PathologyAichi Cancer Center Research InstituteNagoyaJapan
  3. 3.Pathology and Molecular DiagnosticsAichi Cancer Center HospitalNagoyaJapan
  4. 4.Department of Surgery IINagoya University School of MedicineNagoyaJapan

Personalised recommendations